Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.
http://www.priceseries.com/trade/CHMA-Chiasma-Inc-stock-gains-61-percent-a-Trade-Record-by-priceSeries-2019021320190320.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments